These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 25268732)

  • 41. Post-finasteride syndrome: a surmountable challenge for clinicians.
    Traish AM
    Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
    Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
    J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
    Wolff H; Kunte C
    MMW Fortschr Med; 1999 Sep; 141(37):38-40. PubMed ID: 10897972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re: inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
    Kaplan SA
    J Urol; 2014 Mar; 191(3):752. PubMed ID: 24522062
    [No Abstract]   [Full Text] [Related]  

  • 45. On call. I have read several news reports that claim finasteride, which I take for my prostate problem, can cause permanent impotence. Should I be concerned?
    Kormos W
    Harv Mens Health Watch; 2013 Jan; 17(6):2. PubMed ID: 23807950
    [No Abstract]   [Full Text] [Related]  

  • 46. Finasteride for hair loss: a review.
    Gupta AK; Venkataraman M; Talukder M; Bamimore MA
    J Dermatolog Treat; 2022 Jun; 33(4):1938-1946. PubMed ID: 34291720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
    Seale LR; Eglini AN; McMichael AJ
    J Drugs Dermatol; 2016 Apr; 15(4):414-9. PubMed ID: 27050696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.
    Gupta AK; Talukder M; Williams G
    J Dermatolog Treat; 2022 Nov; 33(7):2946-2962. PubMed ID: 35920739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
    Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
    Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M;
    J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Androgens and hair loss.
    Alsantali A; Shapiro J
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):246-53. PubMed ID: 19396986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
    Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
    Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.
    Ganzer CA; Jacobs AR; Iqbal F
    Am J Mens Health; 2015 May; 9(3):222-8. PubMed ID: 24928450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Finasteride adverse effects: An update].
    Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
    Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia.
    Kim S; Eum J; Yang H; Jung H
    J Control Release; 2019 Dec; 316():1-11. PubMed ID: 31689460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women.
    Lee SW; Juhasz M; Mobasher P; Ekelem C; Mesinkovska NA
    J Drugs Dermatol; 2018 Apr; 17(4):457-463. PubMed ID: 29601622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients.
    Hu R; Xu F; Sheng Y; Qi S; Han Y; Miao Y; Rui W; Yang Q
    Dermatol Ther; 2015; 28(5):303-8. PubMed ID: 26031764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature.
    Suchonwanit P; Iamsumang W; Leerunyakul K
    J Dermatolog Treat; 2022 Mar; 33(2):643-648. PubMed ID: 32538225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.